{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:45:07Z","timestamp":1792615507585,"version":"4.5.0"},"reference-count":160,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted in response to food intake that acts biologically by binding to GLP-1 receptors. The primary function of GLP-1 is to stimulate insulin secretion and inhibit glucagon secretion, which helps limit after-meal spikes in blood glucose. GLP-1 reduces intestinal contractility, slows down gastrointestinal motility and emptying, and also acts directly on the hypothalamus, thereby regulating appetite and food intake. Due to its metabolic effects, GLP-1 forms the basis of medications currently used to treat type 2 diabetes (T2DM) and obesity. However, it has also been observed that the use of GLP-1 agonists in the treatment of obesity or diabetes has a beneficial effect on comorbid respiratory conditions. This narrative review analyzes the scientific literature and describes the most recent information on the impact of GLP-1 receptor agonist (GLP-1 RA) therapies on the most common respiratory disorders\u2014both the beneficial and undesirable effects. We discuss evidence that acute lung injury, COVID-19, pulmonary fibrosis, asthma, chronic obstructive pulmonary disease (COPD), and obstructive sleep apnea can benefit from therapies with various GLP-1 RAs. They can complement existing lung-targeted treatments, but as research progresses, they are likely to play an ever more important role in the treatment of respiratory diseases.<\/jats:p>","DOI":"10.3390\/ijms27135803","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:55:11Z","timestamp":1782780911000},"page":"5803","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9597-454X","authenticated-orcid":false,"given":"Ewelina","family":"Russjan","sequence":"first","affiliation":[{"name":"Department of Respiration Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawi\u0144skiego 5, 02-106 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-5912","authenticated-orcid":false,"given":"Dominika","family":"Zaj\u0105c","sequence":"additional","affiliation":[{"name":"Department of Respiration Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawi\u0144skiego 5, 02-106 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9608-4736","authenticated-orcid":false,"given":"Katarzyna","family":"Kaczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Respiration Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawi\u0144skiego 5, 02-106 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bph.15485","article-title":"Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands","volume":"179","author":"Tanday","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_3","unstructured":"Collins, L., and Costello, R.A. (2026, May 15). Glucagon-Like Peptide-1 Receptor Agonists, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","article-title":"Metabolic Messengers: Glucagon-like peptide 1","volume":"3","author":"Gribble","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Laurindo, L.F., Barbalho, S.M., Guiguer, E.L., de Souza, M.S.S., de Souza, G.A., Fidalgo, T.M., Ara\u00fajo, A.C., de Souza Gonzaga, H.F., de Bortoli Teixeira, D., and de Oliveira Silva Ullmann, T. (2022). GLP-1a: Going beyond Traditional Use. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020739"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/crj.13372","article-title":"Use of GLP1RAs and occurrence of respiratory disorders: A meta-analysis of large randomized trials of GLP1RAs","volume":"15","author":"Wei","year":"2021","journal-title":"Clin. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13098-023-01118-6","article-title":"The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: A meta-analysis of randomized controlled trials","volume":"15","author":"Yu","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_9","first-page":"L374","article-title":"GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery","volume":"265","author":"Richter","year":"1993","journal-title":"Am. J. Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting","volume":"48","author":"Waser","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1210\/en.2012-1786","article-title":"Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats","volume":"154","author":"Mallo","year":"2013","journal-title":"Endocrinology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"bqaa201","DOI":"10.1210\/endocr\/bqaa201","article-title":"GLP-1 Receptor Signaling Differentially Modifies the Outcomes of Sterile vs Viral Pulmonary Inflammation in Male Mice","volume":"161","author":"Sato","year":"2020","journal-title":"Endocrinology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., and LeRoith, D. (2023). Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent. Front Immunol., 14.","DOI":"10.3389\/fimmu.2023.1148209"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1139\/cjpp-2025-0148","article-title":"Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective","volume":"103","year":"2025","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e194751","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Jani\u0107, M., \u0160krgat, S., Harlander, M., Lunder, M., Jane\u017e, A., Pantea Stoian, A., El Tanani, M., Maggio, V., and Rizzo, M. (2024). Potential Use of GLP-1 and GIP\/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at? Medicina (Kaunas). Medicina, 60.","DOI":"10.3390\/medicina60122030"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4172\/2161-105X.1000194","article-title":"Oxidative Stress and Therapeutic Development in Lung Diseases","volume":"4","author":"Villegas","year":"2014","journal-title":"J. Pulm. Respir. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Oh, Y.S., and Jun, H.S. (2017). Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010026"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Marcon, L.M.R., and Mazzieri, A. (2025). Anti-Inflammatory and Anti-Oxidative Effects of GLP1-RAs and SGLT2i: The Guiding Star Towards Cardiovascular Protection in Type 2 Diabetes. Immuno, 5.","DOI":"10.3390\/immuno5010011"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"bvaf075","DOI":"10.1210\/jendso\/bvaf075","article-title":"Effect of GLP-1 RA and SGLT2I on Biomarkers of Oxidative Stress in T2DM: A Systematic Review and Meta-analysis","volume":"9","author":"Wei","year":"2025","journal-title":"J. Endocr. Soc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/eje.0.1460863","article-title":"The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects","volume":"146","author":"Hui","year":"2002","journal-title":"Eur. J. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/14728214.2011.616493","article-title":"Emerging GLP-1 receptor agonists","volume":"16","author":"Lund","year":"2011","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann. Intern Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: A systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse Effects of GLP-1 Receptor Agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev. Diabet. Stud."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4103\/2230-8210.111625","article-title":"Glucagon-like peptide-1 analogues: An overview","volume":"17","author":"Gupta","year":"2013","journal-title":"Indian J. Endocrinol. Metab. Medknow"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.diabres.2011.01.004","article-title":"GLP-1 receptor agonists today","volume":"93","author":"Marre","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1378\/chest.07-2134","article-title":"Mortality rates for patients with acute lung injury\/ARDS have decreased over time","volume":"133","author":"Zambon","year":"2008","journal-title":"Chest"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.rcl.2022.06.005","article-title":"Pathogenesis, Imaging, and Evolution of Acute Lung Injury","volume":"60","author":"Kligerman","year":"2022","journal-title":"Radiol. Clin. N. Am."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Verma, N., Hochhegger, B., Mukhopadhyay, S., Teixeira, E., Silva Torres, P.P., and Mohammed, T.L. (2025). Acute Lung Injury. J. Thorac. Imaging., 40.","DOI":"10.1097\/RTI.0000000000000820"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-025-02127-9","article-title":"Advances in acute respiratory distress syndrome: Focusing on heterogeneity, pathophysiology, and therapeutic strategies","volume":"10","author":"Ma","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1016\/j.apsb.2022.06.003","article-title":"The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs\u2014Therapeutic potential exploration in lung injury","volume":"12","author":"Pang","year":"2022","journal-title":"Acta Pharm. Sin. B. Chin. Acad. Med. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Dumitrescu, P., and Kosmider, B. (2026). The Anti-Inflammatory Role of GLP-1 RAs in Acute Lung Injury and Acute Respiratory Distress Syndrome. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27072922"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ejphar.2016.10.016","article-title":"Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice","volume":"791","author":"Zhou","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"E568","DOI":"10.1152\/ajpendo.00292.2020","article-title":"Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein","volume":"319","author":"Zhou","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"L368","DOI":"10.1152\/ajplung.00041.2023","article-title":"Liraglutide pretreatment attenuates sepsis-induced acute lung injury","volume":"325","author":"Baer","year":"2023","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104645","DOI":"10.1016\/j.micpath.2020.104645","article-title":"The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice","volume":"150","author":"Bai","year":"2021","journal-title":"Microb. Pathog."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/SHK.0000000000002285","article-title":"Liraglutide alleviates acute lung injury and mortality in pneumonia-induced sepsis through regulating surfactant protein expression and secretion","volume":"61","author":"Guo","year":"2024","journal-title":"Shock"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3601454","DOI":"10.1155\/2018\/3601454","article-title":"GLP-1 Analogue Liraglutide Enhances SP-A Expression in LPS-Induced Acute Lung Injury through the TTF-1 Signaling Pathway","volume":"2018","author":"Zhu","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"175730","DOI":"10.1016\/j.ejphar.2023.175730","article-title":"Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis","volume":"949","author":"Wang","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41374-018-0170-0","article-title":"Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function","volume":"99","author":"Xu","year":"2019","journal-title":"Lab. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5694\/mja2.50674","article-title":"COVID-19 acute respiratory distress syndrome (ARDS): Clinical features and differences from typical pre-COVID-19 ARDS","volume":"213","author":"Gibson","year":"2020","journal-title":"Med. J. Aust."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.2337\/dc21-1351","article-title":"Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19","volume":"44","author":"Wander","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/1753-0407.13359","article-title":"Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis","volume":"15","author":"Nassar","year":"2023","journal-title":"J. Diabetes"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Chen, Y., Lv, X., Lin, S., Arshad, M., and Dai, M. (2022). The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.895458"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gonikman, D., and Kustovs, D. (2023). Antidiabetic Drug Efficacy in Reduction of Mortality during the COVID-19 Pandemic. Medicina, 59.","DOI":"10.3390\/medicina59101810"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1549","DOI":"10.1002\/hsr2.1549","article-title":"The impact of preadmission\/prediagnosis use of GLP-1 receptor agonists on COVID-19 mortality in patients with diabetes: A systematic review and meta-analysis","volume":"6","author":"Kow","year":"2023","journal-title":"Health Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Greco, S., Monda, V.M., Valpiani, G., Napoli, N., Crespini, C., Pieraccini, F., Marra, A., and Passaro, A. (2023). The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study. Biomedicines, 11.","DOI":"10.3390\/biomedicines11082292"},{"key":"ref_53","first-page":"6459","article-title":"Oxidative stress and inflammation in COVID-19: Potential application OF GLP-1 receptor agonists","volume":"27","author":"Abudalo","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_54","first-page":"2977","article-title":"GLP-1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK\/NF-\u03baB signaling pathways in streptozotocin-induced diabetic rats","volume":"41","author":"Ma","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/1440-1681.13361","article-title":"The pivotal relation between glucagon-like peptides, NF\u03baB and inflammatory bowel disease","volume":"47","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Chen, X., Huang, Q., Feng, J., Xiao, Z., Zhang, X., and Zhao, L. (2021). GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-\u03baB signalling pathway. J. Int. Med. Res., 49.","DOI":"10.1177\/0300060521992981"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"152822","DOI":"10.1016\/j.bbrc.2025.152822","article-title":"GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance","volume":"789","author":"Ngabea","year":"2025","journal-title":"Biochem Biophys. Res. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2024.12.003","article-title":"The immunopathogenesis of a cytokine storm: The key mechanisms underlying severe COVID-19","volume":"82","author":"Hiti","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus","volume":"57","author":"Hogan","year":"2014","journal-title":"Diabetologia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0735-1097(19)32472-6","article-title":"Liraglutide and semaglutide attenuate inflammatory cytokines interferon-gamma, tumor necrosis factor-alpha, and interleukin-6: Possible mechanism of decreasing cardiovascular risk in diabetes mellitus","volume":"73","author":"Tan","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_61","first-page":"342","article-title":"Meta-analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy","volume":"18","author":"Liu","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1111\/bcp.14063","article-title":"Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy","volume":"85","author":"Brock","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide exerts a potent antiinflammatory effect","volume":"97","author":"Chaudhuri","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/dia.2010.0048","article-title":"Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus","volume":"13","author":"Wu","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00395-015-0465-x","article-title":"Gliptin and GLP-1 analog treatment improves survival and vascular inflammation\/dysfunction in animals with lipopolysaccharide-induced endotoxemia","volume":"110","author":"Steven","year":"2015","journal-title":"Basic Res. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00210-015-1124-3","article-title":"Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes\/macrophages","volume":"388","author":"Machnik","year":"2015","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/1871530321666210809153558","article-title":"Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent Potential Therapeutic Approaches for COVID-19. Endocr Metab Immune Disord Drug Targets","volume":"22","author":"Alshanwani","year":"2022","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Hinchliffe, N.W., Sabat, Z.J., Bewick, M., and Feenie, J. (2025). GLP-1 receptor agonists in the management of COVID-19 and long COVID for patients with underlying metabolic disorders. Med. Res. Arch. Knowl. Enterp. J., 13.","DOI":"10.18103\/mra.v13i4.6406"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wang, J.-L., Lee, C.-C., and Ko, W.-C. (2024). Lower Risks of Long COVID and Mortality with GLP-1RAs in Adults with Type 2 Diabetes: Insights into Infectious, Autoimmune, Cardiovascular, Neurological, and Psychiatric Diseases. Bohrium.","DOI":"10.2139\/ssrn.5044989"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Parimon, T., Yao, C., Stripp, B.R., Noble, P.W., and Chen, P. (2020). Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072269"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Confalonieri, P., Volpe, M.C., Jacob, J., Maiocchi, S., Salton, F., Ruaro, B., Confalonieri, M., and Braga, L. (2022). Regeneration or Repair? The Role of Alveolar Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF). Cells, 11.","DOI":"10.3390\/cells11132095"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1002\/mco2.744","article-title":"Pulmonary fibrosis: Pathogenesis and therapeutic strategies","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e066354","DOI":"10.1136\/bmj-2021-066354","article-title":"Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis","volume":"377","author":"Liu","year":"2022","journal-title":"Br. Med. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.intimp.2014.07.010","article-title":"Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-\u03baB in mice","volume":"22","author":"Gou","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1038\/s41598-020-74912-1","article-title":"GLP-1 receptor agonist ameliorates experimental lung fibrosis","volume":"10","author":"Toba","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1186\/s12967-024-05753-z","article-title":"GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome\/PFKFB3-driven glycolysis interaction and histone lactylation","volume":"22","author":"Liu","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"115480","DOI":"10.1016\/j.intimp.2025.115480","article-title":"Dual-sensitive gelatin-coated chitosan microparticles for targeted semaglutide pulmonary delivery: A novel approach to enhancing anti-inflammatory and anti-fibrotic effects","volume":"165","author":"Hamad","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_80","unstructured":"(2026, May 26). 2025 GINA Strategy Report\u2014Global Initiative for Asthma\u2014GINA. Available online: https:\/\/ginasthma.org\/2025-gina-strategy-report\/."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100062","DOI":"10.1016\/j.pharmr.2025.100062","article-title":"Asthma therapeutics: Past, present, and future","volume":"77","author":"Rhoads","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Russjan, E. (2024). The Role of Peptides in Asthma-Obesity Phenotype. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063213"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Palma, G., Sorice, G.P., Genchi, V.A., Giordano, F., Caccioppoli, C., D\u2019oria, R., Marrano, N., Biondi, G., Giorgino, F., and Perrini, S. (2022). Adipose Tissue Inflammation and Pulmonary Dysfunction in Obesity. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137349"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1002\/j.2040-4603.2023.tb00252.x","article-title":"From Beneath the Skin to the Airway Wall: Understanding the Pathological Role of Adipose Tissue in Comorbid Asthma-Obesity","volume":"13","author":"Wang","year":"2023","journal-title":"Compr. Physiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/JAA.S282284","article-title":"Dysregulated Metabolism in the Pathophysiology of Non-Allergic Obese Asthma","volume":"14","author":"McCravy","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_86","first-page":"e30812","article-title":"Beneficial Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Asthma: A Literature Review","volume":"14","author":"Kanwar","year":"2022","journal-title":"Cureus"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"120772","DOI":"10.1016\/j.cca.2025.120772","article-title":"Peptide drugs for obesity and type 2 diabetes mellitus: An overview of clinical trials","volume":"581","author":"Barzgar","year":"2026","journal-title":"Clin. Chim. Acta"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Menzella, F., Cottini, M., and Chan, R. (2025). Unraveling the obesity-asthma link: A new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease. J. Int. Med. Res., 53.","DOI":"10.1177\/03000605251392717"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"20195","DOI":"10.3390\/ijms160920195","article-title":"Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-\u03baB (NF-\u03baB) Signaling Pathway in Mice","volume":"16","author":"Zhu","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jaci.2017.11.043","article-title":"Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo","volume":"142","author":"Toki","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1111\/all.14879","article-title":"Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice","volume":"76","author":"Toki","year":"2021","journal-title":"Allergy"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"102003","DOI":"10.1016\/j.pupt.2021.102003","article-title":"Glucagon-like peptide 1 receptor (GLP-1R) agonist relieved asthmatic airway inflammation via suppression of NLRP3 inflammasome activation in obese asthma mice model","volume":"67","author":"Hur","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"15601","DOI":"10.1038\/s41598-019-51648-1","article-title":"Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model","volume":"9","author":"Park","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/JAA.S478329","article-title":"Glucagon-Like Peptide 1 Receptor (Glp1r) Deficiency Does Not Appreciably Alter Airway Inflammation or Gut-Lung Microbiome Axis in a Mouse Model of Obese Allergic Airways Disease and Bariatric Surgery","volume":"18","author":"Kim","year":"2025","journal-title":"J. Asthma Allergy"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/cea.14252","article-title":"Dual GIPR and GLP-1R agonist tirzepatide inhibits aeroallergen-induced allergic airway inflammation in mouse model of obese asthma","volume":"53","author":"Toki","year":"2023","journal-title":"Clin. Exp. Allergy"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1111\/all.16402","article-title":"Endogenous Glucagon-Like Peptide-1 Receptor and Glucose-Dependent Insulinotropic Polypeptide Receptor Signaling Inhibits Aeroallergen-Induced Innate Airway Inflammation","volume":"79","author":"Toki","year":"2024","journal-title":"Allergy"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/17425255.2026.2632668","article-title":"Pharmacological interactions between asthma and T2DM therapies: Clinical and metabolic implications","volume":"22","author":"Matera","year":"2026","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_98","first-page":"853","article-title":"Preliminary asthma-related outcomes following glucagon-like peptide 1 agonist therapy","volume":"110","author":"Khan","year":"2017","journal-title":"Int. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2337\/db21-0688","article-title":"Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study","volume":"71","author":"Ciudin","year":"2022","journal-title":"Diabetes"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.rmed.2019.06.015","article-title":"Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients","volume":"154","author":"Rogliani","year":"2019","journal-title":"Respir. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1164\/rccm.202004-0993OC","article-title":"Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists","volume":"203","author":"Foer","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/dc20-1794","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients with Type 2 Diabetes","volume":"44","author":"Albogami","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamainternmed.2024.5982","article-title":"Antidiabetic Medication and Asthma Attacks","volume":"185","author":"Lee","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"109080","DOI":"10.1016\/j.diabres.2021.109080","article-title":"Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials","volume":"183","author":"Wang","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_105","first-page":"607","article-title":"The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and\/or Obesity: A Meta-Analysis","volume":"37","author":"Zhang","year":"2024","journal-title":"BioMed Environ. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.jaip.2024.05.002","article-title":"Association of Novel Antihyperglycemic Drugs Versus Metformin With a Decrease in Asthma Exacerbations","volume":"12","author":"Kimura","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1080\/02770903.2024.2372600","article-title":"Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database","volume":"61","author":"Cazzola","year":"2024","journal-title":"J. Asthma."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Cheng, Y.S., Chung, C.H., Kuo, S.M., Lin, C.P., Weng, T.H., Su, S.C., Lu, C.H., Kuo, F.C., Chien, W.C., and Liang, Y.J. (2025). Glucagon-like peptide-1 receptor agonists linked to a reduced risk of developing asthma among patients with type 2 diabetes. Ther. Adv. Endocrinol. Metab., 16.","DOI":"10.1177\/20420188251400536"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1007\/s12325-025-03175-x","article-title":"The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity","volume":"42","author":"Kaplan","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1513\/AnnalsATS.202309-836OC","article-title":"Glucagon-like Peptide 1 Receptor Agonists and Asthma Exacerbations: Which Patients Benefit Most?","volume":"21","author":"Wang","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Wang, T., Wang, J.H., Kinlaw, A.C., Wyss, R., Pate, V., Gou, Z., Buse, J.B., Keet, C.A., Kosorok, M.R., and St\u00fcrmer, T. (2025). Glucagon-like Peptide-1 Receptor Agonists in Asthma Exacerbations: An Application of High-Dimensional Iterative Causal Forest to Identify Subgroups. Pharmacoepidemiol. Drug Saf., 34.","DOI":"10.1002\/pds.70192"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"108197","DOI":"10.1016\/j.rmed.2025.108197","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review","volume":"245","author":"Cooper","year":"2025","journal-title":"Respir. Med."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Yu, Z., Gu, B., Zhang, J., Jin, W., Wan, H., and Jin, W. (2026). Novel antidiabetic agents and the risk of respiratory diseases: A systematic review and meta-analysis of 27 randomized controlled trials. Front Med., 12.","DOI":"10.3389\/fmed.2025.1721311"},{"key":"ref_114","unstructured":"(2026, May 26). Study Details|NCT05254314|Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-Related, Symptomatic Asthma (GATA-3)|ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05254314."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60968-9","article-title":"Chronic obstructive pulmonary disease","volume":"379","author":"Decramer","year":"2012","journal-title":"Lancet"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1900164","DOI":"10.1183\/13993003.00164-2019","article-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The GOLD science committee report 2019","volume":"53","author":"Singh","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/1479972317736294","article-title":"Obesity and metabolic syndrome in COPD: Is exercise the answer?","volume":"15","author":"James","year":"2018","journal-title":"Chron. Respir. Dis."},{"key":"ref_118","first-page":"464","article-title":"Obesity in COPD: Comorbidities with Practical Consequences?","volume":"15","author":"Zewari","year":"2018","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/1744666X.2026.2625967","article-title":"The role of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in chronic obstructive pulmonary disease","volume":"22","author":"Mah","year":"2026","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12931-026-03569-7","article-title":"GLP-1RAs: Antidiabetic drug crossover-new hope for chronic inflammatory airway diseases","volume":"27","author":"Chen","year":"2026","journal-title":"Respir. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"100449","DOI":"10.1016\/j.metop.2026.100449","article-title":"GLP-1 receptor agonists and obstructive lung disease: Beyond metabolic control to respiratory outcomes","volume":"29","author":"Georgakopoulou","year":"2026","journal-title":"Metab. Open."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3892\/mmr.2017.6618","article-title":"Overexpression of GLP-1 receptors suppresses proliferation and cytokine release by airway smooth muscle cells of patients with chronic obstructive pulmonary disease via activation of ABCA1","volume":"16","author":"Sun","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.2147\/COPD.S175145","article-title":"Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients","volume":"13","author":"Huang","year":"2018","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1210\/en.2013-1666","article-title":"Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice","volume":"154","author":"Viby","year":"2013","journal-title":"Endocrinology"},{"key":"ref_125","first-page":"bvz034","article-title":"Glucagon-Like Peptide 1 and Atrial Natriuretic Peptide in a Female Mouse Model of Obstructive Pulmonary Disease","volume":"4","author":"Svendsen","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Skurikhin, E.G., Pershina, O.V., Pakhomova, A.V., Pan, E.S., Krupin, V.A., Ermakova, N.N., Vaizova, O.E., Pozdeeva, A.S., Zhukova, M.A., and Skurikhina, V.E. (2019). Endothelial Progenitor Cells as Pathogenetic and Diagnostic Factors, and Potential Targets for GLP-1 in Combination with Metabolic Syndrome and Chronic Obstructive Pulmonary Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051105"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41385-020-0262-1","article-title":"Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPAR\u03b3-FOXA2-phosphatase signaling","volume":"13","author":"Choi","year":"2020","journal-title":"Mucosal. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/COPD.S350133","article-title":"Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease","volume":"17","author":"Hilberg","year":"2022","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e071380","DOI":"10.1136\/bmj-2022-071380","article-title":"Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: Population based cohort study","volume":"379","author":"Pradhan","year":"2022","journal-title":"Br. Med. J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1164\/rccm.202303-0491OC","article-title":"Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes","volume":"208","author":"Foer","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamainternmed.2024.7811","article-title":"Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes","volume":"185","author":"Ray","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"ref_132","first-page":"550543","article-title":"The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study","volume":"17","author":"Heatley","year":"2026","journal-title":"Pragmat. Obs. Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1136\/thorax-2023-221040","article-title":"Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD","volume":"79","author":"Yen","year":"2024","journal-title":"Thorax"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.wjorl.2015.08.001","article-title":"Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome","volume":"1","author":"Knauert","year":"2015","journal-title":"World J. Otorhinolaryngol. Head. Neck Surg."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Dragonieri, S., Portacci, A., Quaranta, V.N., Carratu, P., Lazar, Z., Carpagnano, G.E., and Bikov, A. (2024). Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Syndrome Management: A Narrative Review. Diseases, 12.","DOI":"10.3390\/diseases12090224"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Wrzesie\u0144, A., Andrzejewski, K., Jampolska, M., and Kaczy\u0144ska, K. (2024). Respiratory Dysfunction in Alzheimer\u2019s Disease-Consequence or Underlying Cause? Applying Animal Models to the Study of Respiratory Malfunctions. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042327"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"101996","DOI":"10.1016\/j.smrv.2024.101996","article-title":"Obstructive sleep apnea and obesity: A review of epidemiology, pathophysiology and the effect of weight-loss treatments","volume":"78","author":"Messineo","year":"2024","journal-title":"Sleep Med. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.arbres.2025.02.014","article-title":"Is Obstructive Sleep Apnea in People Without Obesity a Unique Disease? Arch Bronconeumol","volume":"61","author":"Malhotra","year":"2025","journal-title":"Arch. Bronconeumol."},{"key":"ref_139","first-page":"93","article-title":"Obstructive Sleep Apnea and Obesity: Implications for Public Health","volume":"1","author":"Jehan","year":"2017","journal-title":"Sleep Med. Disord."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1164\/rccm.202007-2906ED","article-title":"Weight Loss Is Integral to Obstructive Sleep Apnea Management. Ten-Year Follow-up in Sleep AHEAD","volume":"203","author":"Tasali","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med. Am. Thorac. Soc."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5114\/amsad\/161170","article-title":"GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: Can new allies face an old enemy?","volume":"8","author":"Papaetis","year":"2023","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"zsad224","DOI":"10.1093\/sleep\/zsad224","article-title":"Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: A revolution or a pipe dream?","volume":"46","author":"Grunstein","year":"2023","journal-title":"Sleep"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14656566.2024.2437525","article-title":"Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: A narrative review","volume":"26","author":"Gould","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/MCP.0000000000001208","article-title":"Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea","volume":"31","author":"Mimoto","year":"2025","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1080\/14656566.2025.2574848","article-title":"The impact of GLP-1 agonists on sleep disorders: Spotlight on sleep apnea","volume":"26","author":"Mifsud","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"102119","DOI":"10.1016\/j.smrv.2025.102119","article-title":"Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: A systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Matics","year":"2025","journal-title":"Sleep Med. Rev."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tcm.2024.03.003","article-title":"The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action","volume":"34","author":"Alexiadou","year":"2024","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Sultana, R., Sissoho, F., Kaushik, V.P., and Raji, M.A. (2022). The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome. Life, 12.","DOI":"10.3390\/life12081222"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Le, K.D.R., Le, K., and Foo, F. (2024). The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review. Pharmacy, 12.","DOI":"10.3390\/pharmacy12010011"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12967-025-06302-y","article-title":"Glucagon-like Peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"23","author":"Yang","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.sleep.2025.02.010","article-title":"Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials","volume":"129","author":"Kow","year":"2025","journal-title":"Sleep Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"zsae280","DOI":"10.1093\/sleep\/zsae280","article-title":"Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: A meta-analysis","volume":"48","author":"Li","year":"2025","journal-title":"Sleep"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2484048","DOI":"10.1080\/20018525.2025.2484048","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: A systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Altobaishat","year":"2025","journal-title":"Eur. Clin. Respir. J."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: The SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int. J. Obes."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s11325-022-02768-y","article-title":"Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea","volume":"27","author":"Jiang","year":"2023","journal-title":"Sleep Breath"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/dom.70209","article-title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","volume":"28","author":"Giblin","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(26)00967-0","article-title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): A double-blind, randomised, phase 3 trial","volume":"407","author":"Bajaj","year":"2026","journal-title":"Lancet"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5803\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:13:51Z","timestamp":1783138431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/13\/5803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":160,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27135803"],"URL":"https:\/\/doi.org\/10.3390\/ijms27135803","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}